130A.T
Veritas In Silico Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 434.00
+0.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | — | — | 235.0M | 360.0M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Expenses | ||||
| R&D Expense | — | — | — | — |
| SG&A Expense | 281.9M | 272.3M | 235.0M | 186.2M |
| General & Admin Expense | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 281.9M | 272.3M | 235.0M | 186.2M |
| Cost and Expenses | — | — | 447.0M | 323.0M |
| Operating Income (EBIT) | (437.0M) | (396.0M) | (212.0M) | 37.0M |
| Non-Operating | ||||
| Interest Income | 6.0M | 5.7M | 1.0M | 14.0K |
| Interest Expense | — | — | — | — |
| Net Interest Income | — | — | — | — |
| Other Non-Op Income/Expense | — | — | (20.7M) | (1.7M) |
| Non-Operating Income (excl Interest) | 351.0K | 391.0K | 452.0K | 261.0K |
| EBT (Pre-Tax Income) | (598.3M) | (421.9M) | (233.6M) | 35.9M |
| Income Tax Expense | 3.7M | 3.7M | 2.9M | 2.9M |
| Bottom Line | ||||
| Net Income | (602.0M) | (425.0M) | (236.0M) | 33.0M |
| Earnings from Cont. Ops | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (602.0M) | (425.0M) | (236.0M) | 33.0M |
| Per Share | ||||
| Basic EPS | (¥93) | (¥66) | (¥37) | ¥6 |
| Diluted EPS | (¥93) | — | — | ¥6 |
| Revenue Per Share | — | — | ¥37 | ¥65 |
| Shares | ||||
| Basic Shares Outstanding | 6.5M | 6.5M | 6.4M | 5.5M |
| Diluted Shares Outstanding | — | — | — | — |
| Profitability Metrics | ||||
| EBITDA | (198.1M) | (380.1M) | (196.4M) | 63.9M |
| D&A | 15.9M | 15.9M | 15.6M | 26.9M |
| EBIT | (437.0M) | (396.0M) | (212.0M) | 37.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026